Ataxia Telangiectasia Clinical Trial
Official title:
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangectasia (A-T).
The EryDex System (EDS) is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EryDex) which is infused into the patient. In the placebo arm, the subjects will receive autologous erythrocytes prepared with the EDS process using a placebo solution. Upon completion of all screening assessments for eligibility, subjects meeting all selection criteria at baseline will be randomized in a 1:1 fashion to EryDex or placebo. Approximately 86 subjects 6- to 9-years-old, approximately 43 per group, will be randomized. Approximately 20 subjects 10 years of age and above, 10 per treatment group, may also be enrolled. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
| Active, not recruiting |
NCT04991701 -
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
|
||
| Active, not recruiting |
NCT05531890 -
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
| Completed |
NCT05252819 -
Whole Body MRI for Cancer Surveillance in A-T
|
||
| Recruiting |
NCT03357978 -
Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia
|
N/A | |
| Withdrawn |
NCT02309632 -
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
|
N/A | |
| Not yet recruiting |
NCT06324877 -
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside
|
N/A | |
| Not yet recruiting |
NCT01075438 -
Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients
|
N/A | |
| Completed |
NCT03962114 -
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia
|
Phase 2 | |
| Completed |
NCT04513002 -
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis
|
Phase 2 | |
| Completed |
NCT05471310 -
Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia
|
||
| Active, not recruiting |
NCT04870866 -
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
|
Phase 2 | |
| Recruiting |
NCT03563053 -
Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
|
Phase 3 | |
| Recruiting |
NCT05692622 -
Home-based Complex Intervention for Children With Ataxia Telangiectasia
|
N/A | |
| Recruiting |
NCT04037189 -
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
|
||
| Not yet recruiting |
NCT04887311 -
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
|
Phase 2 | |
| Active, not recruiting |
NCT00951886 -
The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally
|
N/A | |
| Recruiting |
NCT03759678 -
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
|
Phase 2 | |
| Recruiting |
NCT01052623 -
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
|
Phase 4 |